Search - tctmd.com

Displaying 21 - 40 of 79

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for September 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

October 01, 2020

TCTMD’s Top 10 Most Popular Stories for December 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2019

December 31, 2019

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

News Daily News

Year in Review: Digital Health and A-fib Ablation Top 2019 Heart Rhythm News

December 19, 2019

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Presentation TCT 2019

LAA Closure vs. NOACs: Pros and Cons, PRAGUE 17, and Additional Trials

Presenter: Vivek Reddy

September 26, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

TCTMD’s Top 10 Most Popular Stories for June 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

June 28, 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presentation TVT 2019

Critical Appraisal of the Advantages and Limitations of Warfarin, NOACs, and Ablation in Patients With Non-Valvular Atrial Fibrillation

Presenter: DJ Lakkireddy

June 13, 2019

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Device-Related Thrombus and LAA Closure: Rare but Dangerous

News Daily News

Device-Related Thrombus and LAA Closure: Rare but Dangerous

Yael L. Maxwell

May 09, 2019

Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works

News Daily News

Continuing Anticoagulation During TAVR: New Data Offer a Glimpse of What Works

April 16, 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

News Conference News EHRA 2019

Thromboembolic Risks High in Patients With A-fib, Valvular Disease

March 25, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

TCTMD’s Top 10 Most Popular Stories for February 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

March 01, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

News Daily News

Continuing Anticoagulation During TAVR in A-fib Patients May Be Safe, Study Suggests

January 09, 2019

The Biggest News of 2018: TCTMD’s Top 10

News Daily News

The Biggest News of 2018: TCTMD’s Top 10

December 31, 2018

News Opinion Conversations in Cardiology

Conversations in Cardiology: Can a Patient With Tissue Valves Switch From Warfarin to a NOAC?

November 16, 2018

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

News Daily News

DOACs Safe, Effective in A-fib Patients With Preexisting LAA Thrombus

October 04, 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No – NOACs Are Strongly Preferred to LAA Closure!

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.